Seagate Technology Holdings PLC – Consensus Indicates Potential 11.8% Upside

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Seagate Technology Holdings PLC with ticker code (STX) now have 19 confirmed analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 82 and 35 with the average target price sitting at $67.47. Now with the previous closing price of $60.34 this now indicates there is a potential upside of 11.8%. There is a 50 day moving average of $63.84 while the 200 day moving average is $64.94. The company has a market capitalization of $12,600m. Company Website: https://www.seagate.com

The potential market cap would be $14,088m based on the market consensus.

Seagate Technology Holdings plc provides data storage technology and solutions in Singapore, the United States, the Netherlands, and internationally. It provides mass capacity storage products, including enterprise nearline hard disk drives (HDDs), enterprise nearline solid state drives (SSDs), enterprise nearline systems, video and image HDDs, and network-attached storage drives. The company also offers legacy applications comprising Mission Critical HDDs and SSDs; external storage solutions under the Seagate Ultra Touch, One Touch, and Expansion product lines, as well as under the LaCie brand name; desktop drives; notebook drives, DVR HDDs, and gaming SSDs. In addition, it provides Lyve edge-to-cloud mass capacity platform. The company sells its products primarily to OEMs, distributors, and retailers. Seagate Technology Holdings plc was founded in 1978 and is based in Dublin, Ireland.

The company has a dividend yield of 4.43% with the ex dividend date set at 21-3-2023 (DMY).

Other points of data to note are a P/E ratio of 22.52, revenue per share of 44.22 and a 5.99% return on assets.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    Shield Therapeutics plc, a leader in specialty pharma, boosts ACCRUFeR® sales for iron deficiency in the US while optimizing financial strategies for growth.

      Search

      Search